µÚ39¾íµÚ1ÆÚ
CHINESE
ÖлªÖÐ
OF
ҽҩѧ¿¯
MEDICINE
Vol£®39No£®1Jan£®2021
2021Äê1ÔÂA£ÒCHIVEST£ÒADITIONALCHINESE
DOI£º10£®13193/j£®issn£®1673-7717£®2021£®01£®023
Áù¾ý×ÓÌÀÁªºÏ°×ÈýÏ©ÊÜÌåÞ׿¹¼Á¶Ô·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´ÁÙ´²Ô¤ºó
IL£4¡¢IL£10±í´ïµÄÓ°Ïì¼°IFN£¦Ã¡¢
ÁõÃô£¬Â¬ÌïÌð
£¨ÖÐÄÏ´óÑ§ÏæÑÅҽѧԺ¸½Êôº£¿ÚÒ½Ôº£¬º£ÄϺ£¿Ú570208£©
IL£4¡¢IL£10±í´ïµÄÓ°ÕªÒª£ºÄ¿µÄÁù¾ý×ÓÌÀÁªºÏ°×ÈýÏ©ÊÜÌåÞ׿¹¼Á¶Ô·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´ÁÙ´²Ô¤ºó¼°IFN£¦Ã¡¢
Ïì¡£·½·¨Ñ¡Ôñ2016Äê4Ô¡ª2018Äê3ÔÂÔÚÒ½ÔºÕï¶ÏΪ·ÎÆ¢ÆøÐéÐÍÏø´»¼¶ù¹²120Àý£¬°´ÕÕÈë×é˳ÐòËæ»ú¾ù·ÖΪÁ½×飬·Ö×é·½·¨ÒÀ¾ÝËæ»úÊý×Ö±í·¨¡£Èë×éºó¶ÔÕÕ×鏸Óè°×ÈýÏ©ÊÜÌåÞ׿¹¼Áµ¥Ò©ÖÎÁÆ£»Í¬Ê±ÖÎÁÆ×éʹÓÃÁù¾ý×ÓÌÀÁªºÏ°×ÈýÏ©ÊÜÌåÞ׿¹¼ÁÖÎÁÆ¡£¹Û²ìÁ½×黼ÕßÁÙ´²ÁÆÐ§£¬²¢¶ÔÁ½×黼ÕßÖÎÁÆÇ°ºóÖÐÒ½Ö¢ºò»ý·Ö¡¢·Î¹¦ÄܽøÐбȽϣ¬¼ì²â»¼ÕßѪÇ壬±È½ÏÁ½
IL£4¡¢IL£10¡£½á¹ûÖÎÁÆ×é×ÜÓÐЧÂÊÃ÷ÏÔ¸ßÓÚ¶ÔÕÕ×飬ÁÙ´²ÖÎÁÆÐ§¹ûÃ÷ÏÔÓÅÓÚ¶ÔÕÕ×飨P£¼0.05£©£»×éÖÎÁÆÇ°ºóIFN£¦Ã¡¢
ÖÎÁÆ×éÖÐÒ½Ö¢ºò»ý·Ö½Ï¶ÔÕÕ×éÏÔÖø½µµÍ£¨P£¼0.05£©£»ÖÎÁÆ×é·Î¹¦ÄÜÖ¸±êFEV1¼°PEF¾ù½Ï¶ÔÕÕ×é¸ÄÉÆÏÔÖø£¨P£¼0.05£©£»
IL£10ÏÔÖøÉý¸ß£¬IL£4ÔòÏÔÖø½µµÍ£¨P£¼0.05£©¡£½áÂÛÁù¾ý×ÓÌÀÁªºÏ°×ÈýÏ©ÊÜÌåÞ׿¹¼ÁÓÐЧÖÎÁÆ×é½Ï¶ÔÕÕ×éIFN£¦Ã¡¢
IL£4¡¢IL£10µÄ±í´ï¡£ÓÐЧ¸ÄÉÆIFN£¦Ã¡¢Ìá¸ß·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´ÁÙ´²ÖÎÁÆÐ§¹û¼°ÆäÔ¤ºó£¬
¹Ø¼ü´Ê£ºÁù¾ý×ÓÌÀ£»°×ÈýÏ©ÊÜÌåÞ׿¹¼Á£»·ÎÆ¢ÆøÐé£»Ïø´£»IFN£¦Ã£»IL£4£»IL£10
7717£¨2021£©01-0086-03ÖÐͼ·ÖÀàºÅ£º£Ò256£®12ÎÄÏ×±êÖ¾Â룺AÎÄÕ±àºÅ£º1673-
EffectofLiujunziDecoction£¨Áù¾ý×ÓÌÀ£©CombinedwithLeukotriene£ÒeceptorAntagoniston
ClinicalPrognosisandExpressionsofIFN£¦Ã£¬IL£4andIL£10inChildren
withLung£SpleenQiDeficiency
LIUMin£¬LUTiantian
£¨AffiliatedHaikouHospitalofXiangyaMedicalCollege£¬CentralSouthUniversity£¬Haikou570208£¬Hainan£¬China£©
Abstract£ºObjectiveLiujunziDecoction£¨Áù¾ý×ÓÌÀ£©combinedwithleukotrienereceptorantagonistsontheclinicalprognosisandexpressionsofIFN£¦Ã£¬IL£4andIL£10inchildrenwithlung£spleenQideficiency£®MethodsAtotalof120childrenwithadiagnosisofasthmawithlung£spleenQideficiencysyndromefromApril2016toMarch2018wereenrolledinthisstudy£®Theywererandomlydividedintotwogroupsaccordingtotheenrollmentorder£®Thegroupingmethodwasbasedontherandomnumbertablemethod£®Aftertheenrollment£¬thecontrolgroupwasgivenmonotherapywithleukotrienereceptorantagonist£®ThetreatmentgroupwastreatedwithLiujunziDecoctioncombinedwithleukotrienereceptorantagonist£®Theclinicalefficacyofthetwogroupswasobserved£®TheTCMsyndromescoresandlungfunctionwerecomparedbeforeandaftertreatment£®Theserumofthepatientswasdetected£®ThelevelsofIFN£¦Ã£¬IL£4andIL£10werecomparedbeforeandaftertreatment£®£ÒesultsThetotaleffectiverateofthetreatmentgroupwassignificantlyhigherthanthatofthecontrolgroup£®Theclinicaltreatmenteffectwassignificantlybetterthanthatofthecontrolgroup£¨P£¼0.05£©£®TheTCMsyndromescoreofthetreatmentgroupwassignificantlylowerthanthatofthecontrolgroup£¨P£¼0.05£©£®ThelungfunctionindexesofthetreatmentgroupwereFEV1andPEF£®Comparedwiththatofthecontrolgroup£¬theimprovementwassignificant£¨P£¼0.05£©£®Comparedwiththoseofthecontrolgroup£¬thelevelsofIFN£¦ÃandIL£10weresignificantlyincreased£¬whilethelevelofIL£4wassignificantlydecreased£¨P£¼0.05£©£®ConclusionLiujunziDecoctioncombinedwithleukotrienereceptorantagonistcaneffectivelyimprovetheclinicaltherapeuticeffectandprognosisofasthmachildrenwithlung£spleenQideficiencysyndromeandeffectivelyimprovetheexpressionsofIFN£¦Ã£¬IL£4andIL£10£®
Keywords£ºLiujunziDecoction£¨Áù¾ý×ÓÌÀ£©£»leukotrienereceptorantagonist£»lung£spleenQideficiency£»asthma£»IFN£¦Ã£»IL£4£»IL£10
¡£¾Ýͳ¼Æ£¬Ïø´ÊǶùͯÖÐ×î³£¼ûµÄÂýÐÔ¼²²¡Ö®Ò»½üÄê
À´È«ÇòÏø´»¼Õß³ÊÖðÄêÉÏÉýµÄÇ÷ÊÆ£¬¶ø¶ùÍ¯Ïø´µÄ·¢²¡ÂʸüÊÇ
»ù½ðÏîÄ¿£º¹ú¼ÒÖÐÒ½Ò©¹ÜÀí¾ÖÖÐÒ½Ò©ÐÐÒµ¿ÆÑÐÏîÄ¿£¨20170833£©×÷Õß¼ò½é£ºÁõÃô£¨1983££©£¬Å®£¬ºþÄϦµ×ÈË£¬Ö÷ÖÎҽʦ£¬Ñ§Ê¿£¬Ñо¿·½Ïò£º
¶ù¿Æ¡£
£Û1£2£Ý
Ôö¼ÓÁËÒ»°ëÒÔÉÏ¡£Óë´Ëͬʱ£¬¶ùÍ¯Ïø´µÄ¿ØÖÆÂÊÈ´²»ÈÝÀÖ
¹Û£¬Ò»°ëÒÔÉϵĶùÍ¯Ïø´»¼Õß¾ù³öÏÖ¼±ÐÔ·¢×÷£¬ÖÁÉÙËÄ·ÖÖ®Ò»
£Û4£Ý
µÄ¶ùͯҲÒò´ËÐèÒª¼±¾ÈÖÎÁÆ¡£Ïø´ÏÔÖøÓ°Ïì×ŶùͯµÄ½¡¿µ
£Û5£Ý
·¢Óý£¬Í¬Ê±ÎªÆä¼ÒÍ¥´øÀ´³ÁÖØµÄ¸ºµ£¡£ÔÚÁÙ´²ÖÐËù¼ûÏø´»¼¶ù¶àΪÑǽ¡¿µ×´Ì¬£¬Òò´ËÓÕ·¢Ïø´µÄÒòËØ¶ÔÆäÀ´Ëµ¸üΪÃô¸Ð£¬¶ÔÓÚÕâÖÖ»¼¶ùÀ´Ëµ£¬µ¥´¿µÄʹÓó£ÓõÄÎüÈë¼¤ËØÎÞ·¨ÓÐЧ
£Û3£Ý
86
µÚ39¾íµÚ1ÆÚ
CHINESE
ÖлªÖÐ
OF
ҽҩѧ¿¯
MEDICINE
Vol£®39No£®1Jan£®2021
2021Äê1ÔÂA£ÒCHIVEST£ÒADITIONALCHINESE
£Û6£7£Ý
¡£¿öÇÒ³¤ÆÚʹÓü¤ËضÔÓÚ»¼¶ù½â¾ö¶ùÍ¯Ïø´µÄÕæÕýÎÊÌâ·¢ÏÖÉÙÐíÆøµÀ·ÖÃÚÎÎÞЧ£ºÁÙ´²±íÏÖ¼°Ó°Ïñѧ¹Û²ìÃ÷ÏÔºÃת£¬
Ïñѧδ·¢Ïֱ仯£¬ÈÔ·¢ÏÖ½Ï¶àÆøµÀ·ÖÃÚÎï¡£×ÜÓÐЧÂÊ=£¨ÏÔЧÀ´Ëµ£¬Ò²²»ÀûÓÚÆäÕý³£µÄÉú³¤·¢Óý¡£½üЩÄêÀ´£¬¶àÏîÑо¿¶¼Ö¤
ÀýÊý+ÓÐЧÀýÊý£©/×ÜÀýÊý¡Á100%¡£ÊµÁËÖÐÒ½Ò©ÔÚÏø´·½ÃæµÄ¶ÀÌØ×÷Óá£ÖÐҽѧÈÏÎªÏø´ÊôÓÚ
¡°´Ö¤¡±¡°Ïø²¡¡±·Î¹¦ÄÜ£ºÔÚ»¼¶ùÖÎÁÆÇ°12ÖÜÓëÖÎÁƺó12ÖܲⶨµÚ1Ãë×îµÈ·¶³ë£¬ÆäÃèÊöµÄ¼²²¡»úÀíÓëÏÖ´úËùνµäÐÍÏø
¡°ÄÚÒò¡±¡°ÍâÒò¡±£¬´óºôÆøÁ¿£¨FEV1£©ºÍ×î´óºôÆøÁ÷Á¿£¨PEF£©¡£´ÏàËÆ£¬²¡ÒòÖ÷Òª·ÖΪÄÚÒò°üº¬ÒÅ´«¡¢ÌåÖÆ¡¢·ü
ÖÐÒ½Ö¢×´»ý·Ö£ºÖÎÁÆÇ°12ÖÜÓëÖÎÁƺó12ÖܶԻ¼¶ùÏøÃùÍâ¸ÐÖ÷ÒªÒÔÁùÒùΪÖ÷£¬¼æ¼ûÒûʳ²»½Ú£¬À;ëËùÉË£¬ÄÚ̵µÈÒòËØ£¬
¿ÈËÔ¡¢´Ï¢¡¢¿È̵»ý·Ö¼ÆË㣬¸ù¾ÝÖ¢×´µÄ·Ö¼¶ÎªÃ¿Ò»¸öÖ¸±êÒô¡¢ÉËÇéÖ¾µÈ¡£Í¨¹ýÖÐÒ½µÄÖÎÁÆ£¬¿ÉÒÔÓÐЧ»º½âÏø´ÁÙ´²Ö¢×´£¬°ï
£Û8£Ý
»ý·Ö£¬ÎÞ0·Ö£¬Çá1·Ö£¬ÖÐ2·Ö£¬ÖØ4·Ö¡£Ìá¸ßÉú»îÖÊÁ¿¡£±¾Ñо¿¹Û²ìÁù¾ý×ÓÌÀÁªÖú»¼Õ߻ָ´½¡¿µ£¬
ʵÑéÊÒÖ¸±ê£º²É¼¯»¼¶ùÖÎÁÆÇ°¼°ÖÎÁƺó5¡«8hÄÚµÄÖⲿºÏ°×ÈýÏ©ÊÜÌåÞ׿¹¼Á¶Ô·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´ÁÙ´²Ô¤ºó¼°IFN£
¾²ÂöѪ£¬²ÉÓÃDG5033Aø±êÒÇ£¨ÄϾ©»ª¶«µç×ӿƼ¼¹«Ë¾£©½øÐÐIL£4¡¢IL£10±í´ïµÄÓ°Ï죬¦Ã¡¢ÏÖ±¨µÀÈçÏ¡£
ODÖµ¼ì²â£¬IL£4¡¢IL£10¡£¼ì²â»¼ÕßIFN£¦Ã¡¢1×ÊÁÏÓë·½·¨
1£®4ͳ¼ÆÑ§·ÖÎöÑ¡ÔñSPSS21£®0½øÐÐÊý¾Ýͳ¼Æ£¬Êý¾Ý²ÉÓÃ1£®1Ò»°ã×ÊÁÏѡȡÎÒÔº2017Äê2Ô¡ª2018Äê3ÔÂµÄ·ÎÆ¢
«€x¡ÀsÀ´±íʾ£¬¼ÆÁ¿×ÊÁϵıȽϲÉÓÃt¼ìÑ飬¼ÆÊý×ÊÁÏµÄ±È½Ï²ÉÆäÖÐÄÐ60Àý£¬Æ½¾ùÄêÁ䣨9£®5¡À1£®6£©ÆøÐéÐÍÏø´»¼¶ù120Àý£¬
2
ÓæּìÑ飬P£¼0.05ʱ£¬²îÒì¾ßÓÐͳ¼ÆÑ§ÒâÒå¡£ËꣻŮ60Àý£¬Æ½¾ùÄêÁ䣨8£®5¡À1£®3£©Ëê¡£°´ÕÕÈë×é˳ÐòËæ»ú·ÖΪ
2½á¹ûÿ×é60Àý£¬·Ö×é·½·¨¸ù¾ÝËæ»úÊý×Ö±í·¨£¬Á½×é»ù±¾×ÊÁÏÁ½×飬
2£®1Á½×é·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´»¼ÕßÁÙ´²ÁÆÐ§¶Ô±ÈÖÎÁÆ×é×ܲîÒìÎÞͳ¼ÆÑ§ÒâÒ壨P£¾0.05£©£¬¾ßÓпɱÈÐÔ¡£
ÓÐЧÂÊΪ95£®00%£»¶ÔÕÕ×é×ÜÓÐЧÂÊΪ73£®33%¡£Á½×éÏà±È£¬ÄÉÈë±ê×¼£º·ûºÏÏø´»ù±¾Õï¶Ï±ê×¼£»ÖÐÒ½±æÖ¤ÊôÓÚ·ÎÆ¢Æø
ÖÎÁÆ×é×ÜÓÐЧÂÊÊýÃ÷ÏÔ¸ßÓÚ¶ÔÕÕ×飬ÁÙ´²ÖÎÁÆÐ§¹ûÏÔÖøÓÅÓÚÐéÐÍÏø´£»ÄêÁä7¡«12Ëꣻ»¼¶ù·¨¶¨¼à»¤ÈËÖªÇ鲢ͬÒâ¡£
¶ÔÕÕ×飨P£¼0.05£©¡£¼û±í1¡£Åųý±ê×¼£ººÏ²¢¸Î¡¢ÉöµÈÑÏÖØ¼²²¡£»¶ñÐÔÖ×Áö»¼Õߣ»·¨¶¨¼à
±í1Á½×é·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´»¼ÕßÁÙ´²ÁÆÐ§±È½Ï»¤È˲»Í¬ÒâͬÒâ»ò»¼¶ùÎÞ·¨ÅäºÏÍê³ÉÑо¿Õߵȡ£
µ¥Î»£ºÀý£¨%£©1£®2·½·¨¶ÔÕÕ×黼¶ù¸øÓèÃÏÂ³Ë¾ÌØÄÆÆ¬£¨Ë³¶ûÄþ£¬Éú²ú³§
1´Î¡¤d£1£¬¼Ò£ºÄ¬É³¶«£¬½ø¿ÚÒ©Æ·×¢²áÖ¤ºÅ£ºH20120360£©£¬Ã¿×é±ðÀýÊýÏÔЧÓÐЧÎÞЧ×ÜÓÐЧ
´Î1Ƭ£¨4mg£©£»ÖÎÁÆ×黼¶ùÔÚÃÏÂ³Ë¾ÌØÄÆÆ¬µÄ»ù´¡ÖÎÁÆÉÏÁª6039£¨65£®00£©18£¨30£®00£©3£¨5£®00£©ÖÎÁÆ×é57£¨95£®00£©*
6026£¨43£®33£©18£¨30£®00£©16£¨26£®67£©44£¨73£®33£©¶ÔÕÕ×éÜòÜß9g£¬°×Êõ9g£¬°ëÏÄ9g£¬ºÏÁù¾ý×ÓÌÀ£¨Ò©Îï×é³É£ºÈ˲Î9g£¬
£1
1¼Á¡¤d£¬P£¼0.05¡£³ÂƤ9g£¬¸Ê²Ý6g£©£¬Ë®¼å·þ£¬ÔçÍí¸÷1´Î¡£Á½×黼ע£º*Óë¶ÔÕÕ×é±È½Ï£¬
2£®2Á½×é·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´»¼ÕßÖÎÁÆÇ°ºóÖÐÒ½Ö¢ºò»ý·Ö±È¶ù¸øÓèÖÎÁƹ²3¸öÔ¡£
1£®3¹Û²ìÖ¸±êÁÆÐ§Åжϱê×¼£ºÏÔЧ£ºÁÙ´²±íÏÖ¼°Ó°Ïñѧ֤Ã÷¿ÈËÔ¡¢´Ï¢¡¢¿È̵µÄÖÐÒ½Ö¢ºò»ý·Ö¾ù½Ï¶ÔÕÕ½ÏÖÎÁÆ×éÏøÃùÒô¡¢
×é¸ÄÉÆÏÔÖø£¨P£¼0.05£©¡£¼û±í2¡£Î´·¢ÏÖÆøµÀ·ÖÃÚÎÓÐЧ£ºÁÙ´²±íÏÖ¼°Ó°½ÏǰÎüÊÕ95%ÒÔÉÏ£¬
«€¡Às£©±í2Á½×é·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´»¼ÕßÖÎÁÆÇ°ºóÖÐÒ½Ö¢ºò»ý·Ö±È½Ï£¨xµ¥Î»£º·Ö
×é±ðÖÎÁÆ×é¶ÔÕÕ×é
ÀýÊý6060
ÏøÃùÒô
ÖÎÁÆÇ°2£®67¡À0£®212£®70¡À0£®37
ÖÎÁƺó0£®69¡À0£®27*1£®54¡À0£®44*
#
¿ÈËÔ
ÖÎÁÆÇ°2£®81¡À0£®352£®96¡À0£®34
ÖÎÁƺó0£®72¡À0£®06*1£®35¡À0£®28*
#
´Ï¢
ÖÎÁÆÇ°2£®88¡À0£®332£®86¡À0£®35
ÖÎÁƺó0£®65¡À0£®08*1£®36¡À0£®19*
#
¿È̵
ÖÎÁÆÇ°2£®98¡À0£®232£®76¡À0£®85
ÖÎÁƺó0£®50¡À0£®76*1£®65¡À0£®75*
#
P£¼0.05£»#Óë¶ÔÕÕ×é±È½Ï£¬P£¼0.05¡£×¢£º*ÓëÖÎÁÆÇ°±È½Ï£¬
2£®3
Á½×é·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´»¼ÕßÖÎÁÆÇ°ºó·Î¹¦ÄܱȽÏÖÎ
ÁÆ×éFEV1¼°PEF½Ï¶ÔÕÕ×é¸ÄÉÆÏÔÖø£¨P£¼0.05£©¡£¼û±í3¡£
±í3Á½×é·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´»¼ÕßÖÎÁÆ
«€¡Às£©Ç°ºó·Î¹¦ÄܱȽϣ¨x
×é±ðÖÎÁÆ×é¶ÔÕÕ×éÀýÊý6060FEV1/£¨L£©ÖÎÁÆÇ°1£®29¡À0£®181£®28¡À0£®17ÖÎÁƺó1£®54¡À0£®23*#
0.05£©¡£¼û±í4¡£3ÌÖÂÛ
Ëæ×ÅÏÖ½ñÉç»áÏø´¼²²¡·¢²¡Âʲ»¶ÏÉÏÉý£¬µ¼Ö¶ùͯ»¼Õß²¡ËÀÂʼ°Ö²ÐÂʲ»¶ÏÉÏÉý£¬ÏÔÖøÔö¼ÓÁË»¼¶ùµÄÉú»îÖÊÁ¿¼°Æä¼ÒÈË
£Û9£11£Ý
¡£ÈËÃǶÔÏø´µÄ·¢²¡»úÖÆÒ²²»¶ÏËæ×ÅÏø´·¢²¡»ú¶î¸ºµ£
ÖÆµÄ²»¶ÏÑо¿Ì½Ë÷¡£³ýÒÅ´«¡¢ÃâÒß¡¢»·¾³µÈÒòËØÍ⣬ÏÖ´úÁÙ´²»¹
Tϸ°û¼°·Ê´óϸ°ûµÈ¶àÖÖÆÕ±éÈÏΪ£¬Ïø´ÊÇÓÉÊÈËáÐÔÁ£Ï¸°û¡¢
£Û12£14£Ý
¡£ÔÚ²¡Àí·¢Õ¹ÀàµÄÑ×ÐÔϸ°û¹²Í¬²ÎÓëµÄÆø¹ÜÂýÐÔÑ×Ö¢
ÖУ¬²»Í¬µÄÑ×֢ϸ°ûÏ໥×÷Óã¬ÆøµÀµÄ±íƤϸ°ûÊܵ½ÁËËðÉË£¬ÒýÆð΢Ѫ¹ÜµÄÀ©ÕÅºÍÆäͨ͸ÐÔÉý¸ß£¬×îÖÕÑ×ÐÔϸ°û´ÙÊ¹Ö§Æø¹ÜµÄ
£Û15£18£Ý
¡£Ñо¿ÏÔʾ£¬µ¼Ö¸ò¡²»¶Ï·¢×÷ÏøÊÕËõºÍÆä½á¹¹µÄ±ä»¯£¬
µ¥Î»£ºng¡¤L
IL£10
ÖÎÁƺó8£®77¡À3£®16*25£®88¡À6£®88*
#
£1
PEF/£¨L¡¤s£1£©ÖÎÁÆÇ°3£®33¡À0£®453£®38¡À0£®41ÖÎÁƺó4£®91¡À0£®48*4£®11¡À0£®49*
#
1£®44¡À0£®11*
P£¼0.05£»#Óë¶ÔÕÕ×é±È½Ï£¬P£¼0.05¡£×¢£º*ÓëÖÎÁÆÇ°±È½Ï£¬2£®4
Á½×é·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´»¼ÕßÖÎÁÆÇ°ºóʵÑéÊÒÖ¸±ê±È½ÏIL£4¡¢IL£10¾ù½Ï¶ÔÕÕ×é¸ÄÉÆÏÔÖø£¨P£¼ÖÎÁÆ×éIFN£¦Ã¡¢
«€¡Às£©±í4Á½×é·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´»¼ÕßÖÎÁÆÇ°ºóʵÑéÊÒÖ¸±ê±È½Ï£¨x
×é±ðÖÎÁÆ×é¶ÔÕÕ×é
ÀýÊý6060
IFN£¦Ã
ÖÎÁÆÇ°135£®65¡À14£®59136£®74¡À13£®46
ÖÎÁƺó213£®25¡À18£®79*146£®33¡À16£®98*
#
IL£4
ÖÎÁÆÇ°29£®19¡À8£®7728£®33¡À9£®22
ÖÎÁÆÇ°18£®46¡À4£®9516£®60¡À4£®64
ÖÎÁƺó33£®25¡À4£®68*22£®44¡À6£®65*
#
P£¼0.05£»#Óë¶ÔÕÕ×é±È½Ï£¬P£¼0.05¡£×¢£º*ÓëÖÎÁÆÇ°±È½Ï£¬
87
µÚ39¾íµÚ1ÆÚ
CHINESE
ÖлªÖÐ
OF
ҽҩѧ¿¯
MEDICINE
Vol£®39No£®1Jan£®2021
2021Äê1ÔÂA£ÒCHIVEST£ÒADITIONALCHINESE
IL£4¡¢IL£10ÔÚÏø´²¡Àí»úÖÆÖз¢»Ó´»¼ÕßѪÇåÄÚIFN£¦Ã¡¢
ÖØÒª×÷Óã¬Äܹ»½ÒÊ¾Ïø´²¡Àí½øÕ¹»úÖÆ£¬ÊÇÆÀ¼Û¶ùÍ¯Ïø´ÖØÒªµÄÆÀ¼ÛÖ¸±ê
£Û19£Ý
£®ÁÙ´²Ò½Ñ§Ñо¿Óëʵ¼ù£¬2018£¬3£¨18£©£ºÆø¹ÜÏø´µÄÁÙ´²Ð§¹û£ÛJ£Ý123£124£®
£Û9£ÝÂíЧ¶«£®Áù¾ý×ÓÌÀ¼Ó¼õÖÎÁÆÐ¡¶ùÖ§Æø¹ÜÏø´µÄÁÆÐ§¼°¶ÔÃâÒß¹¦
J£Ý£®È«¿ÆÒ½Ñ§ÁÙ´²Óë½ÌÓý£¬2018£¬16£¨1£©£º82£84£®ÄܵÄÓ°Ïì£Û
£Û10£ÝÕÅÁ¢±ò£®ÖÐÎ÷Ò½½áºÏÖÎÁÆÏø´Õï¶Ï·ÖÎö£ÛJ£Ý£®Òûʳ±£½¡£¬2016£¬3
£¨2£©£º196£197£®
£Û11£ÝÄôÁ¦£¬¸ðÎÀºì£®°×ÈýÏ©ÊÜÌåÞ׿¹¼Á¸ÄÉÆÏø´»¼ÕßÑ×Ö¢¼°ÃâÒß¹¦
2017£¬35£¨6£©£º562£564£¬568£®ÄܵÄЧ¹û·ÖÎö£ÛJ£Ý£®Ò©Ñ§Êµ¼ùÔÓÖ¾£¬
£Û12£ÝÖìϼ£¬¼ÖÎÀ»ª£®è×½ÛÁù¾ý×ÓÌÀ¼Ó¼õÁªºÏɳÃÀÌØÂÞÌæ¿¨ËÉ·ÛÎüÈë
£®ÖйúÃñ¼äÁÆ·¨£¬2018£¬26¼ÁÖÎÁÆÖ§Æø¹ÜÏø´µÄÁÙ´²¹Û²ì£ÛJ£Ý£¨9£©£º63£64£®
£Û13£ÝÁºÑÞ¾ù£¬ÖÜÁ¢Ô¶£¬Íõ¼ÒÕ䣮°×ÈýÏ©Þ׿¹¼ÁÁªºÏÊæÀûµüÔÚÏø´ÖÎÁÆ
2016£¬10£¨16£©£º1£ÖеÄÓ¦ÓÃÒâÒå̽¾¿£ÛJ£Ý£®ÖйúÏÖ´úÒ©ÎïÓ¦Óã¬3£®
£Û14£ÝÍò³Ï£¬Ð¤²¨£®·Î¡¢Æ¢¡¢ÉöÈýÔàͬÖλº½âÆÚÖ§Æø¹ÜÏø´50ÀýÁÙ´²¹Û
J£Ý£®¹ã¶«Ò½Ñ§ÔºÑ§±¨£¬2016£¬34£¨2£©£º194£196£®²ì£Û
£Û15£ÝBUTLE£ÒCT£¬£ÒEYNOLDSAL£¬TOSETTOM£¬etal£®AQuininib
AnalogueandCysteinylLeukotriene£ÒeceptorAntagonistInhibitsVascularEndothelialGrowthFactor£¨VEGF£©£independentAngio-genesisandExertsanAdditiveAntiangiogenic£ÒesponsewithBev-acizumab£ÛJ£Ý£®JBiolChem£¬2017£¬292£¨9£©£º3552£3567£®
£Û16£ÝÕÅ»ÝæÃ£¬ÕÅÀöÄÈ£®°×ÈýÏ©ÊÜÌåÞ׿¹¼ÁÁªºÏÌÇÆ¤Öʼ¤ËØÖÎÁÆÐ¡¶ù¿È
J£Ý£®¼ªÁÖҽҩѧԺѧ±¨£¬2019£¬40£¨3£©£º222£224£®ËÔ±äÒìÐÔÏø´£Û
£Û17£Ý·ëÃô¾ê£®°×ÈýÏ©ÊÜÌåÞ׿¹¼Á°×Èýƽ¶ÔС¶ùÏø´µÄÓÐЧÐÔ̽ÌÖ
£ÛJ£Ý£®´ó¼Ò½¡¿µ£¨ÉÏÑ®°æ£©£¬2017£¬11£¨10£©£º206£®
£Û18£ÝOKUBOK£¬HASHIGUCHIK£¬TAKEDAT£¬etal£®Arandomized
controlledphaseIIclinicaltrialcomparingONO£4053£¬anovelDP1antagonist£¬withaleukotrienereceptorantagonistpranlukastinpatientswithseasonalallergicrhinitis£ÛJ£Ý£®Allergy£¬2017£¬72£¨10£©£º1565£1575£®
£Û19£Ý·®ÕêÓñ£¬ÖÜѩ÷£¬ÏãÀûºì£¬µÈ£®°×ÈýÏ©Þ׿¹¼ÁÁªºÏÎüÈëÊæÀûµüÖÎ
2017£¬33ÁÆÀÏÄêÏø´»¼ÕßµÄÁÙ´²Ð§¹û·ÖÎö£ÛJ£Ý£®ÖйúÉçÇøÒ½Ê¦£¬£¨31£©£º32£33£®
£Û20£ÝÉê¹ãÉú£¬Íõ¾ê£®Áù¾ý×ÓÌÀºÏÓñÆÁ·çÉ¢ÖÎÁƶùÍ¯Ïø´²¢·´¸´ºôÎü
2018£¬33£¨21£©£º3124£3126£®µÀ¸ÐȾµÄ¼ÛÖµ£ÛJ£Ý£®¹âÃ÷ÖÐÒ½£¬
£Û21£Ý²ÜÇåÔÆ£®°×ÈýÏ©Þ׿¹¼ÁÁªºÏÎüÈëÊæÀûµüÖÎÁÆÀÏÄêÏø´µÄÁÙ´²ÑÐ
J£Ý£®ÖÐÎ÷Ò½½áºÏÐÄѪ¹Ü²¡µç×ÓÔÓÖ¾£¬2017£¬5£¨1£©£º87£®¾¿£Û
£Û22£ÝÀîÎÄóÞ£®°×ÈýÏ©Þ׿¹¼ÁÁªºÏÎüÈëÌÇÆ¤Öʼ¤ËضÔÀÏÄêÏø´»¼Õß·Î
£®ÁÙ´²Ò½Ò©ÎÄÏ×µç×ÓÔÓÖ¾£¬2017£¬4¹¦Äܼ°Éú´æÖÊÁ¿µÄÓ°Ïì£ÛJ£Ý£¨40£©£º7876£7877£®
£Û23£ÝFITZPAT£ÒICKAM£¬JACKSONDJ£¬MAUGE£ÒDT£¬etal£®Individ-ualizedtherapyforpersistentasthmainyoungchildren£ÛJ£Ý£®JAllergyClinImmunol£¬2016£¬138£¨6£©£º1608£1618£®
£Û24£Ý¹ùÀ裬±ß¿¡Ã·£®ÁªºÏʹÓð×ÈýÏ©ÊÜÌåÞ׿¹¼ÁÖÎÁƶùͯ¿ÈËÔ±äÒìÐÍ
J£Ý£®ÊµÓÃÁÙ´²Ò½Ò©ÔÓÖ¾£¬2017£¬21£¨3£©£º203£205£®Ïø´µÄÁÙ´²Ñо¿£Û
£Û25£Ý²ÌƼ£®Áù¾ý×ÓÌÀºÏÓñÆÁ·çÉ¢ÖÎÁÆÓ¤Ó×¶ùÏø´²¢·´¸´ºôÎüµÀ¸ÐȾ
J£Ý£®´ó¼Ò½¡¿µ£¨ÖÐÑ®°æ£©£¬2017£¬11£¨6£©£º192£®µÄ¼ÛÖµ£Û
£Û26£ÝCHAUHANBF£¬JEYA£ÒAMANMM£¬SINGHMANNA£¬etal£®Addi-tionofanti£leukotrieneagentstoinhaledcorticosteroidsforadults£®CochraneDatabaseSystandadolescentswithpersistentasthma£ÛJ£Ý£Òev£¬2017£¬3£ºCD010347£®
£Û27£ÝФÀö£®Áù¾ý×ÓÌÀºÏÓñÆÁ·çÉ¢ÖÎÁƶùÍ¯Ïø´²¢·´¸´ºôÎüµÀ¸ÐȾµÄ
J£Ý£®Öйú´¦·½Ò©£¬2017£¬15£¨7£©£º119£120£®¼ÛÖµ£Û
£Û28£ÝĪΤٻ£¬¼ª´óÕ£¬Âí³¯Ï¼£®°×ÈýÏ©ÊÜÌåÞ׿¹¼ÁÁªºÏÎüÈëÐÍÌÇÆ¤ÖÊ
£®ÖйúÏÖ´úÒ©ÎïÓ¦¼¤ËØÖÎÁƶùͯ¿ÈËÔ±äÒìÐÔÏø´ÁÙ´²¹Û²ì£ÛJ£Ý2019£¬13£¨7£©£º106£107£®Óã¬
¡£
ÔÚÏø´²¡Àí¹ý³ÌÖУ¬°×ÈýÏ©ÊÇÒ»ÖÖÖØÒªµÄÑ×ÐÔ·´Ó¦½éÖÊ¡£°×ÈýÏ©¿ÉÒÔÔö¼ÓÆøµÀ×é֯Ѫ¹Üͨ͸ÐÔ£¬´Ù½øð¤Ä¤·ÖÃÚÎïµÄ·ÖʹÊÈËáÐÔÁ£Ï¸°ûÐγɻý¾Û£¬´Ó¶øÒý·¢Æø¹ÜÊÕËõ¡£Õë¶ÔÕâÒ»ÃÚ£¬
²¡ÀíÏÖÏó£¬ÁÙ´²ÖжàÓÃÐÂÒ»´ú·ÇçÞÌ忹Ñ×Ò©°×ÈýÏ©ÊÜÌåÞ׿¹¼Á£¬Æä¿ÉÒÔÓÐЧÒÖÖÆ°×ÈýÏ©µÄ»îÐÔ£¬Ôö¼ÓѪ¹Üͨ͸ÐÔ£¬¼õÉÙÆøµÀÑ×Ö¢½éÖʵIJúÉú£¬×îÖÕ¸ÄÉÆ¶ùÍ¯Ïø´»¼Õߵķι¦ÄÜ¡£µ«µ¥´¿Ê¹Óð×ÈýÏ©ÊÜÌåÞ׿¹¼ÁÓÃÓÚ¶ùÍ¯Ïø´ÖÎÁƵĸöÌåÐÔ²îÒì½Ï´ó£¬ÁÙ´²ÖдæÔÚÒ»²¿·Ö¶ùͯ»¼ÕßÖÎÁÆÐ§¹û²»¼Ñ£¬Ò²´Ó¶øÓ°ÏìÁËÆäÖÎÁÆÒÀ´ÓÐÔ
£Û20£22£Ý
¡£
£¬¡°·ü̵¡±´Ö¤ÔÚÖÐҽѧÖÐÊÇÒ»ÀàÖØÒªµÄ¼²²¡±»ÈÏΪÊÇ´
£Û23£24£Ý
¡£Ö¤·¢²¡×îÖ÷Òª¡¢×îºËÐĵÄÔÒò£¬¹ÊÂÛÖζà´Ó¡°Ìµ¡±ÈëÊÖ¡°Ìµ¡±¶ø×÷ΪһÖÖ²¡Àí²úÎÆä²úÉúÖ÷ÒªÓëÈËÌå·Î¡¢Æ¢¡¢ÉöÈý²Ø
Ïà¹Ø£¬ÆäÖÐÓÈÆäÓë·Î¡¢Æ¢Á½²Ø×îΪÃÜÇС£Æ¢ÎªÉú̵֮Դ£¬·ÎΪ´¢ÌµÖ®Æø¡£Æ¢Ð鯸Èô£¬Ë®Òº²»µÃÔË»¯£¬´æÓÚÌåÄÚ¾ÃÔò»¯Ìµ£»·ÎÖ÷ÆøË¾ºôÆø£¬ÈôÆäÆøÐéÔòÆøÐв»³©£¬Ëཱུʧ˾£¬ÎÞ·¨Ê¹Ë®ÊªÕý³£ÔËÐÐ
£Û25£27£Ý
¡£Í¬Ê±Ð¡¶ù¶àÓÐÏÈÌìÙ÷¸³²»×ã»òºóÌìÊ§Ñø£¬µ¼ÖÂ·ÎÆ¢
£Û28£ÝÐéÈõ£¬ËùÒÔС¶ùÏø´£¬¶àÒÔ·ÎÆ¢ÆøÐéÐÍΪÖ÷¡£Õë¶ÔÕâÒ»ÁÙ´²Ìص㣬±¾Ñо¿ÔÚ°×ÈýÏ©ÊÜÌåÞ׿¹¼ÁµÄ»ù´¡ÉϼÓÓÃÁËÖÐÒ½¾µä·½
¼ÁÁù¾ý×ÓÌÀ£¬°üº¬È˲Ρ¢°×Êõ¡¢ÜòÜß¡¢¸Ê²Ý¡¢°ëÏÄ¡¢³ÂƤ¹²6ζ¡£È˲δó²¹ÔªÆø£¬µ÷ÕûÆøÐ飻°×ÊõºÍÖÐ񾮿£¬Ôïʪ»¯Ìµ£»ÜòÜß½¡Æ¢µ÷ºÍÀûË®ÉøÊª£»°ëÏÄÔïʪ»¯Ìµ£»³ÂƤ½¡Æ¢ÀíÆø£»¸Ê²ÝÇåÈȽⶾ£¬ÖîÒ©£»Áùζҩ¹²×àµ÷ÑøÕýÆø£¬ÐÐÆø»¯ÌµÖ®¹¦Ð§¡£±¾Ñо¿²ÉÓÃÁù¾ý×ÓÌÀÁªºÏ°×ÈýÏ©ÊÜÌåÞ׿¹¼ÁÓëµ¥´¿Ê¹Óð×ÈýÏ©ÊÜÌåÞ׿¹¼ÁÏà¶Ô±È£¬Ñо¿½á¹ûÏÔʾ£¬ÖÎÁÆ×éÖÎÁÆ×ÜÓÐЧÂÊÏÔÖø¸ßÓÚ¶ÔÕÕ×飬ÖÎÁƺóÖÎÁÆ×éÏøÃùÒô¡¢¿ÈËÔ¡¢´Ï¢¡¢¿È̵µÈ
½Ï¶ÔÕÕ×é¶øÑÔ£¬¾ùÖÐÒ½Ö¢ºò»ý·Ö¼°·Î¹¦ÄÜÖ¸±êFEV1¼°PEF£¬
IL£4¡¢IL£10¾ù½ÏµÃµ½ÁËÏÔÖøµÄ¸ÄÉÆ¡£Í¬Ê±ÖÎÁÆ×éIFN£¦Ã¡¢
¶ÔÕÕ×éÒ²¸ÄÉÆÏÔÖø¡£ÌáʾÁù¾ý×ÓÌÀÁªºÏ°×ÈýÏ©ÊÜÌåÞ׿¹¼ÁÖÎÁÆ·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´ÖÎÁÆÐ§¹ûÃ÷È·£¬¿ÉÏÔÖø»º½âÁÙ´²Ö¢×´£¬½µµÍ»¼¶ùÑ×ÐÔ·´Ó¦£¬¸ÄÉÆ·Î¹¦ÄÜ£¬²¢ÓÐÖúÓÚÌá¸ß»úÌåÃâÒß¹¦ÄÜ£¬Ìá¸ß»¼¶ùÔ¤ºó¡£²Î¿¼ÎÄÏ×
£Û1£Ý°²º£Ó¢£®Áù¾ý×ÓÌÀ½áºÏÎ÷Ò©ÖÎÁƶùÍ¯Ïø´µÄÁÆÐ§£ÛJ£Ý£®ÁÙ´²Ò½Ñ§
2018£¬3£¨13£©£º122£123£®Ñо¿Óëʵ¼ù£¬
£Û2£ÝMIWAN£¬NAGANOT£¬OHNISHIH£¬etal£®AnOpen£Label£¬
Multi£Institutional£¬£ÒandomizedStudytoEvaluatetheAdditiveEffectofaLeukotriene£ÒeceptorAntagonistonCoughScoreinPa-tientswithCough£VariantAsthmaBeingTreatedwithInhaledCorti-costeroids£ÛJ£Ý£®KobeJMedSci£¬2018£¬64£¨4£©£ºE134£E139£®£Û3£ÝÂíݼ£¬¼ÍÎÄÄÈ£®ÓñÆÁ·çÉ¢ºÏÁù¾ý×ÓÌÀ¼Ó¼õ¸¨ÖúÖÎÁÆÐ¡¶ùÏø´»º½â
J£Ý£®ÖÐÒ½¶ù¿ÆÔÓÖ¾£¬2018£¬14£¨2£©£º32£35£®ÆÚ184ÀýÁÙ´²¹Û²ì£Û
£Û4£ÝµË»ÆÖУ®ÓñÆÁ·çÉ¢ºÏÁù¾ý×ÓÌÀ¼Ó¼õ¸¨ÖúÖÎÁÆÐ¡¶ùÏø´»º½âÆÚÁÙ
£®½¡¿µ±Ø¶Á£¬2018£¨17£©£º6£®´²ÓÐЧÂÊ·ÖÎö£ÛJ£Ý
£Û5£ÝÌÕº£Ñ࣮Áù¾ý×ÓÌÀÁªºÏ³£¹æÁÆ·¨ÖÎÁÆÄÑÖÎÐÔÏø´ÁÙ´²¹Û²ì£ÛJ£Ý£®
2017£¬26£¨22£©£º180£182£®Ë«×ãÓë±£½¡£¬
£Û6£ÝÁõÑÇ×ð£¬ÕÅ𩣬ѦÕ÷£¬µÈ£®Áù¾ý×ÓÌÀºÏÓñÆÁ·çÉ¢ÖÎÁÆÏø´Ç¨ÑÓÆÚµÄ
£®ÖйúÖÐÎ÷Ò½½áºÏ¶ù¿ÆÑ§£¬2019£¬11£¨2£©£º117£121£®ÁÙ´²Ñо¿£ÛJ£Ý
£Û7£ÝÌïÊÀÁ«£®°×ÈýÏ©ÊÜÌåÞ׿¹¼ÁÁªºÏÎüÈëÓü¤ËØÖÎÁÆÖÐÖØ¶ÈÏø´µÄ
£®ÑøÉú±£½¡Ö¸ÄÏ£¬2019£¨35£©£º293£®Ó¦ÓÃЧ¹ûÑо¿£ÛJ£Ý
£Û8£Ý¹¬Õñ»ª£®è×½ÛÁù¾ý×ÓÌÀ¼Ó¼õºÍɳÃÀÌØÂÞÌæ¿¨ËÉ·ÛÎüÈë¼ÁÖÎÁÆÖ§
88
Ïà¹ØÍÆ¼ö£º